B
Bullisch
Bullisch · 25%BLFS
$26.69
Szenariopreis
$38.610
+1.355 (+3.51%)Zum Schluss
Loading chart…
- Hoch
- 38.830
- Eröffnung
- 37.160
- Volumengewichteter Durchschnittskurs
- 38.13
- Volumen
- 4.45M
- Marktkap.
- 944.41M
- Tief
- 36.950
- Umsatz
- 169.53M
- EV/EBITDA, TTM
- 164.02
BioLife Solutions, Inc. is a developer and supplier of cell processing tools and services for the cell and gene therapy (CGT) market. The Company facilitates the commercialization of new therapies by supplying solutions that maintain the health and function of biologic materials during the collection, development, manufacturing and distribution. Its CryoStor freeze media and HypoThermosol hypothermic storage media are optimized to preserve cells in the cell and gene therapy market. Its Sexton cell processing product line includes human platelet lysates (hPL) for cell expansion. Its CellSeal closed systems are purpose-built rigid containers used in cell and gene therapy (CGT). Its CryoCase cryo-compatible transparent rigid containers are designed for closed-system fill and retrieval, and automated cell processing machines. The Company's ThawSTAR product line comprises a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags.
KI-Analyse of BioLife Solutions, Inc. (BLFS)
HaltenBioLife Solutions Inc is currently not a strong buy due to recent downgrades and insider selling, despite a significant year-to-date increase of 56.13%.
Analystenbewertungen (3)
-13.88% Abwärtspotenzial
Kaufen
2 Kaufen
1 Halten
0 Verkaufen
Aktuell: 38.61
Tief
32.00
Durchschnitt
33.25
Hoch
34.00
Benchmark
Halten
—
2026-08-10
Benchmark
2026-08-10
Kursziel
—
Halten
Jefferies
Halten
$31
2026-07-23
Jefferies
2026-07-23
Kursziel
$31
Halten
H.C. Wainwright
Neutral
$31
2026-07-23
H.C. Wainwright
2026-07-23
Kursziel
$31
Neutral
TD Cowen
Halten
$31
2026-07-22
TD Cowen
2026-07-22
Kursziel
$31
Halten
Craig-Hallum
Halten
$31
2026-07-22
Craig-Hallum
2026-07-22
Kursziel
$31
Halten
Bewertungskennzahlen
Das aktuelle erwartete KGV von BioLife Solutions, Inc. (BLFS) beträgt 238.10, verglichen mit dem 5-Jahres-Durchschnitt von -160.78.
Alphio-AI-Kursszenarien für BLFS
Szenariopreise sind das letzte monatliche Prognoseband des laufenden Jahres. Die Wahrscheinlichkeiten sind feste Modellgewichte (25 / 50 / 25), keine Garantien.
Whales, die BLFS halten
Event-Zeitleiste
News
8.510-06FoolFreshworks Joins S&P SmallCap 600 Index
2.009-23NASDAQ.COMBiotech Stocks Reach 52-Week Highs Driven by Key Catalysts
8.509-11PRnewswireInvestor Rights Law Firm Investigates Multiple Companies for Potential Violations
8.508-18NASDAQ.COMBiotech Stocks Reach 52-Week Highs Driven by Key Catalysts
7.007-28PRnewswireInvestor Rights Law Firm Investigates Multiple Companies
BLFS FAQ – beantwortet von Alphio AI
BioLife Solutions, Inc. is a developer and supplier of cell processing tools and services for the cell and gene therapy (CGT) market. The Company facilitates the commercialization of new therapies by supplying solutions that maintain the health and function of biologic materials during the collection, development, manufacturing and distribution. Its CryoStor freeze media and HypoThermosol hypothermic storage media are optimized to preserve cells in the cell and gene therapy market. Its Sexton cell processing product line includes human platelet lysates (hPL) for cell expansion. Its CellSeal closed systems are purpose-built rigid containers used in cell and gene therapy (CGT). Its CryoCase cryo-compatible transparent rigid containers are designed for closed-system fill and retrieval, and automated cell processing machines. The Company's ThawSTAR product line comprises a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. It operates in the Healthcare sector (ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS industry).
BioLife Solutions Inc is currently not a strong buy due to recent downgrades and insider selling, despite a significant year-to-date increase of 56.13%.
3 analysts cover BLFS: 2 rate it Buy, 1 Hold and 0 Sell. The average price target is 33.25.
Community
Mehr ↗Noch keine Beiträge
Registriere dich oder melde dich an, um mitzudiskutierenDiese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.